Sirolimus‐based immunosuppression in liver transplantation for hepatocellular carcinoma: A meta‐analysis

Wenhua Liang, Dongping Wang, Xiaoting Ling, Andrew Allen Kao, Yuan Kong, Yushu Shang, Zhiyong Guo, Xiaoshun He – 30 September 2011 – Sirolimus (SRL) is a novel immunosuppressant with antitumor properties. We performed a meta‐analysis to determine whether SRL can improve patient survival and decrease the risks of tumor recurrence in patients with a pretransplant diagnosis of hepatocellular carcinoma (HCC). We searched databases for controlled clinical trials assessing the survival and oncological benefits of SRL for liver transplant recipients with pretransplant HCC.

Subscribe to